Treating metastatic disease with a modified herpesvirus

Using bacteria or viruses to control tumors is an old idea, and many such biotherapeutic agents have been designed and tested in cell and animal models. Safety concerns are paramount in this work, and most candidates with oncolytic properties have remained sidelined at the preclinical stage because, despite a general tropism towards cancer cells, they retain some ability to infect normal host cells or to cause systemic disease. Here, Nakamura and colleagues describe a second-generation derivative of the herpes simplex virus (HSV-1) that, they suggest, may be ready to clear this hurdle. A previously engineered form of HSV-1, deficient in the viral gene for the enzyme ribonucleotide reductase, replicated preferentially in liver tumor cells, which divide rapidly and possess sufficient pools of deoxynucleotides to support efficient viral replication. The newer recombinant virus, Myb34.5, has this same defect but also carries an engineered form of the g134.5 gene. The product of this gene allows the virus to circumvent a host cell defense mechanism that would otherwise shut down protein synthesis in infected cells. In Myb34.5, g134.5 is expressed under control of the Myb promoter, which is active in cycling cells, leaving the virus with extremely limited ability to proliferate in healthy host tissues. Nakamura et al. show that injection of Myb34.5 into mice carrying a high load of metastatic liver cells affords these animals considerable protection and significantly extends their survival. Even when provided at doses 10-fold higher than a rapidly fatal dose of wild-type HSV-1, Myb34.5 did not kill or paralyze treated mice. The authors caution, however, that neither mice nor other experimental animals provide fully adequate models for HSV-1 infection. Hence, viral toxicity in humans remains a possibility.


Contact: John Ashkenas
Journal of Clinical Investigation

Page: 1

Related biology news :

1. Treating strokes with blood cord cells holds promise, Saint Louis University rat study shows
2. Treating precancerous breast cells may prevent onset of cancer
3. Treating bacterial infections can help asthmatics
4. Treating acne with antibiotics leads to resistance
5. Study Provides Guidance For Treating Patients With Brain Aneurysms
6. Relapses Prevented In Mouse Model Of Multiple Sclerosis: Research Aimed At Treating Relapses In Human MS
7. Mechanism Of Protein Folding Unraveled, With Eventual Implications For Treating Diseases Caused By Folding Errors
8. Gene Therapy In A Liquid May Lead To Quicker, Easier Methods For Treating Disease
9. New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin Americas Most Devastating Diseases
10. Study Finds Shorter Period Of Drug Therapy Is Effective In Treating Stomach Ulcers Caused By H. Pylori
11. Treating Anemia Reduces Risk Of Death For People With HIV

Post Your Comments:

(Date:1/4/2019)... ... January 03, 2019 , ... ... cell culture models into their drug discovery research workflows with biology ranging from ... in vivo relevancy of in vitro studies, they create several challenges that need ...
(Date:12/27/2018)... ... December 27, 2018 , ... uBiome, the leader in microbial ... JP Morgan 37th Annual Healthcare Conference in San Francisco, which brings together industry ... community. , Since its origin in 1983, the JP Morgan Healthcare Conference ...
(Date:12/20/2018)... TRIANGLE PARK, N.C. (PRWEB) , ... December 20, ... ... have been enhanced through upgraded processes and the completion of a new usability/observation ... Evaluations with the goal of ensuring medical devices and drug delivery devices/combination products ...
Breaking Biology News(10 mins):
(Date:12/13/2018)... ... 2018 , ... Microbial Discovery Group LLC (MDG) has expanded ... of their strategic plan and an important milestone in increasing their Bacillus fermentation ... MDG within the $44 Billion human probiotic market. This plan is a vital ...
(Date:12/5/2018)... ZOETERMEER, Netherlands (PRWEB) , ... December 05, 2018 , ... ... last week paid tribute to in the European Parliament by Carlos Moedas, the European ... High-Level Conference EU Research and Innovation in Our Daily Lives, Commissioner Moedas spoke at ...
(Date:11/29/2018)... ... ... RAGS, today announced the closing of a $1.5 million Second Seed round investment. ... board member Jeremy Andrus, CEO of Traeger Grills, as well as James Ho of ... to accelerate its growth and expand the product line. RAGS has now raised a ...
(Date:11/26/2018)... ... 2018 , ... USARAD Holdings Inc., the leading US Joint ... Radiologic founders) among other healthcare investors exhibits at the Radiological Society of North ... The company is proud to announce a 10 year anniversary since its formation ...
Breaking Biology Technology:
Cached News: